|Bid||128.720 x 1000|
|Ask||128.810 x 1000|
|Day's Range||127.47 - 129.47|
|52 Week Range||113.52 - 184.00|
|Beta (3Y Monthly)||1.23|
|PE Ratio (TTM)||15.18|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||178.35|
Biotech stocks are already making some big waves this year. That's because M&A activity is already surging. Drawn by some big-time values, some of the world's biggest pharmaceutical firms have gone shopping for beaten-down biotech bargains. Already, we've seen Bristol-Meyers (NYSE:BMY) score Celgene (NASDAQ:CELG) for a cool $74 billion in a game-changing acquisition. More recently, Eli Lilly (NYSE:LLY) announced that it was pushing harder into cancer treatments with an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). The question on everyone's minds is "who is next?" InvestorPlace - Stock Market News, Stock Advice & Trading Tips With plenty of biotech stocks still trading for peanuts and coffers overflowing at the major pharma's, more M&A activity is guaranteed. And while betting on a buyout may be a fool's errand, there are plenty of biotech stocks out there are on my best stocks to invest in list anyway. A buyout would be icing on the cake. * Morgan Stanley: 7 Risky Stocks to Sell Now But which ones have the potential to snagged up because they are so good? Here are five biotech stocks that could be buy-out candidates. Source: Shutterstock ### Seattle Genetics (SGEN) With oncology and cancer on the minds of many of the biggest names pharma, biotech stock Seattle Genetics (NASDAQ:SGEN) could once again be in play. SGEN has one drug available for patients -- Adcetris -- which is used to treat Stage III/IV classical Hodgkin lymphoma. Sales of Adcetris continue to grow rapidly. In the last reported quarter, revenues for the drug jumped by over 60% year-over-year. Even better is that number of indications, combinations and other uses for Adcetris have grown like weeds. SGEN continue to rack up more approvals and "breakthrough" designations for the drug. All of this has only made the medicine more lucrative for the biotech stock. As if that wasn't enough for big pharma to be salivating at the firm, Seattle Genetics has been able to pivot its technology towards other forms of cancer. The firm has numerous drugs targeting urothelial, cervical, breast and multiple myeloma cancer varieties. Here again, SGEN has been quite successful in moving its drugs through the FDA's hoops. Given growing sales of Adcetris and its heavy-duty cancer-focused pipeline, any biopharma looking to make a splash in oncology would seriously be considering SGEN stock. With a market cap of just over $11 billion, Seattle Genetics could one of the next biotech stocks to be bought out. Source: Shutterstock ### Agios Pharmaceuticals (AGIO) Keeping with the cancer buy-out theme, Agios Pharmaceuticals (NASDAQ:AGIO) makes an intriguing biotech buyout candidate. AGIO has two cancer therapies on the market. Its latest, Tibsovo, has been approved for those acute myeloid leukemia patients with an IDH1 mutation. The other -- Idhifa -- is for acute myeloid leukemia patients who also test positive for an IDH2 mutation. The firm basically has a one-two punch for this specific variety of leukemia. And while the drugs are new, prescriptions are growing, with Tibsovo seeing a 100% quarter-over-quarter increase in its short life span. That makes it a buyout candidate alone. Tibsovo is wholly owned by Agios. However, the real kicker is that Idhifa came via a partnership with Celgene. Celgene -- soon to be Bristol Meyers -- must continue to pay royalties on sales from the drug via a tiered structure that gets into the mid-teens. Given its buyout of CELG, BMY may just want to control the whole pie, and with AGIO's market cap sitting at just over $3 billion, it's an easy pill to swallow. And with the two medicines, BMY would be getting a healthy pipeline of additional cancer therapies as well as some rare disease work for a song. * 10 Stocks You Can Set and Forget (Even In This Market) Given that, there's a good chance that AGIO gets the nod. No wonder why shares have jumped higher since both CELG's and LOXO's buyout bids. Source: Shutterstock ### Jazz Pharmaceuticals (JAZZ) It's very rare to find biotech stocks trading for bargain-basement valuations. But that's just what is happening at Jazz Pharmaceuticals (NASDAQ:JAZZ). Today, you can snag JAZZ stock for forward P/E of under 10. JAZZ has five drugs on the market, with narcolepsy drug Xyrem being a blockbuster. Sales of Xyrem continue to grow and are expected to surpass $1.4 billion this year. At the same time, its portfolio of hematology/oncology drugs are proven to be winners as well and are helping JAZZ realize a double-digit EPS growth rate. Acute myeloid leukemia treatment Vyxeos, which only launched last year, is set to pull in roughly $100 million in sales for the full year 2018 and more than $200 million this year. Adding to this is JAZZ's pending March approval for its new drug covering excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Another late-stage candidate for cataplexy in narcolepsy should hit regulatory approval at the end of the year. With a rich drug portfolio and pipeline, JAZZ is a rarity among biotech stocks. It's profitable -- so much so that the firm has authorized a $400 million buyback program. That's after it already repurchased over $600 million in shares. Analysts estimate that a dividend could even be coming next. Featuring a market cap of less than $8 billion, JAZZ would be an easy and profitable tuck-in for almost any big pharma stock. Source: Shutterstock ### Neurocrine Biosciences (NBIX) A rare miss for Neurocrine Biosciences (NASDAQ:NBIX) sent shares crashing this year and left the firm with a $7.5 billion market cap. But NBIX's pain could end up being AbbVie's (NASDAQ:ABBV) gain. Over the summer, NBIX and ABBV received an FDA approval for their drug Orilissa, which is used in the treatment of pain associated with endometriosis. The drug is currently wrapping up trials for the treatment of uterine fibroids. Analysts think the drug has blockbuster potential with annual sales of around $1 billion. On its own, NBIX has a blockbuster in Ingrezza. The drug is used to treat tardive dyskinesia -- which is marked by jerky movements of the face and body out of a patient's control. The problem is tardive dyskinesia is a side effect of many depression, schizophrenia and other mental health drugs. This is a huge market, and Ingrezza sales are taking off. Management at Neurocrine estimates that they'll be able to pull in over $400 million in Ingrezza sales in 2018. And NBIX has a full pipeline of other drugs in various stages of trials. With a buyout, ABBV gets full access to Orilissa without royalty and milestone fees for future indications. Secondly, Ingrezza is quickly becoming a major money marker for NBIX. That would fill a nice hole in AbbVie's revenue stream and would help pay for the deal over the long haul. * The 7 Best Stocks in the Entrepreneur Index All in all, given its low market cap, hefty cash balance and marketed drugs, AbbVie may end up swallowing NBIX whole. Source: Shutterstock ### BioMarin Pharmaceutical (BMRN) When politicians and pundits often talk about the high price of drugs and mention therapies costing more than $400,000 per year, odds are, they are talking about rare and orphan diseases. For biotech stocks, targeting these diseases -- which sometimes can affect very small population sizes -- it can mean plenty of long-term revenues down the road. Given the research required to crack these afflictions, the high drug prices are more than justified. BioMarin (NASDAQ:BMRN) is one biotech stock that has made rare diseases its specialty. The firm has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. Rare disease medications come with longer exclusivity rights and by focusing here, BMRN basically ensures patient protection versus generic competition. At the same time, these drugs pull in some big-time revenues. For example, this year, BioMarin expects to make more than $1.5 billion in sales with its top five drugs. Meanwhile, the biotech stocks pipeline is rich as well with drugs for hemophilia and sanfilippo in late-stage trials. Because of its focus, profitability and rich rare disease pipeline, BioMarin has long been considered a buy candidate. With big pharma finally starting to spend some dough, that takeover may finally happen. At the time of writing, Aaron Levitt had a long position in CELG and JAZZ ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 5 Biotech Stocks That Could Face M&A Next! appeared first on InvestorPlace.
# Jazz Pharmaceuticals PLC ### NASDAQ/NGS:JAZZ View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for JAZZ with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding JAZZ is favorable, with net inflows of $13.74 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
As corporate diversity issues are in the spotlight, a small group will assemble at the J.P. Morgan Healthcare Conference to build a network of current and potential LGBTQ board members.
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
DUBLIN and CAMBRIDGE, Mass., Jan. 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted Jazz an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using Codiak's engEx™ precision engineering platform for exosome therapeutics.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of Read More...
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Jazz Pharmaceuticals stock toppled to its lowest point in nearly two years Friday after the FDA delayed its excessive sleepiness drug for narcolepsy and obstructive sleep apnea patients.
DUBLIN, Dec. 21, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its new drug application (NDA) for solriamfetol as a treatment to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA). The FDA determined that an NDA submission made by Jazz during the course of discussions regarding draft labeling for solriamfetol constitutes a major amendment to the NDA, resulting in a three-month extension of the PDUFA goal date to provide time for a full review of the submission.
DUBLIN, Dec. 19, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the company will be webcasting its corporate presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. A live audio webcast of the presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archive of the webcast will be available for at least one week following the presentation on the Investors section of the company's website at http://www.jazzpharmaceuticals.com.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...
Jazz Pharmaceuticals (JAZZ). is the type of stock that should protect you in case of a bear market while still offering upside for as long as the bear holds off, suggests growth stock expert Scott Chan, editor of Investing Daily's The Complete Investor.
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors endured a torrid quarter, which certainly propelled them to adjust their equity holdings so as to maintain the desired risk profile. As […]
DUBLIN, Dec. 10, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that its Board of Directors has authorized a $400 million increase in the company's share repurchase program, which the company intends to use over time based on market conditions and other factors. Prior to this increased authorization, the Board of Directors had authorized $620 million under the company's share repurchase program, of which $194 million had been utilized through September 30, 2018. Since that date, the company has utilized the remainder of that prior authorization.
Bruce Cozadd has been the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) since 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, Read More...
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
DUBLIN, Nov. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the first patient has been enrolled in a Phase 3 clinical trial evaluating the efficacy and safety of JZP-258 for the treatment of idiopathic hypersomnia, a sleep disorder characterized by chronic and disabling excessive daytime sleepiness (daytime periods of irrepressible need to sleep or daytime lapses into sleep) that is not caused by other conditions known to induce excessive daytime sleepiness. Other symptoms of idiopathic hypersomnia may include prolonged nighttime sleep, long and unrefreshing naps and difficulty waking up from nocturnal sleep or daytime naps.
Nine abstracts, including two oral presentations, accepted for Jazz hematology/oncology portfolio, focusing on leukemia and complications of stem cell transplantation DUBLIN , Nov. 28, 2018 /PRNewswire/ ...